The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or ...

Monday - Friday: 12:00 - 13:00 SIN/HK | 0600 - 07:00 CET Samia Bouazza, CEO of Multiply Group, shares insights on the company's strategic acquisition of Ghitha Holding and 2PointZero through a ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve ...

Please provide your email address to receive an email when new articles are posted on . The most common ocular adverse events with antibody-drug conjugates involve the ocular surface. The mainstay of ...

Multiply Group PJSC has agreed to acquire two other Abu Dhabi firms backed by the emirate’s largest listed company, in a share-swap transaction that it said will create an entity holding assets of ...

Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, announces the launch of its new IR820 and IR870 infrared dye antibody conjugates. For the ...

Forbes contributors publish independent expert analyses and insights. I'm a senior tech contributor who writes about science and technology Multiply Labs and Universal Robots have entered a ...

Please provide your email address to receive an email when new articles are posted on . Patients on ADCs with known ocular side effects require close ophthalmic monitoring. A cycle of topical ...

Tendam is Spain's second-largest apparel group by market share and one of Europe’s leading omnichannel apparel groups. Tendam’s 12 well-established owned fashion brands offer diversity and ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

Trastuzumab deruxtecan in frontline maintenance Dr Moore discussed the challenge of prioritizing biomarkers when multiple are present: “I would always prioritize a ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high ...